ArQule, Inc. to Present at Jefferies and Needham Investment Conferences

Presentations will highlight ASCO Phase 2 data with ARQ 197 in non-small cell lung cancer

WOBURN, Mass., Jun 08, 2010 (BUSINESS WIRE) -- ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Jefferies 2010 Global Life Sciences Conference on June 9, 2010, beginning at 9:30 a.m. eastern time, and at the 9th Annual Needham Healthcare Conference on June 10, 2010, beginning at 10:40 a.m. eastern time. Both conferences will be held in New York.

The presentations will be web cast and may be accessed through the investor relations section of the Company's website, http://www.arqule.com.

These presentations follow the company's presentation on June 5, 2010 of data from a Phase 2 clinical trial at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data showed encouraging overall survival and prolonged progression-free survival results with ARQ 197 in combination with erlotinib among patients with advanced, refractory non-small cell lung cancer. Patients with non-squamous cell carcinoma histology, who account for approximately 70 percent of NSCLC patients, experienced particular benefit.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule's lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. The Company is also conducting Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. The Company's pre-clinical pipeline includes a compound designed to inhibit the B-RAF kinase. ArQule's current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP(TM)), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase. The most advanced AKIP(TM) program is focused on the discovery of inhibitors of fibroblast growth factor receptor (FGFR).

SOURCE: ArQule, Inc.

ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
www.ArQule.com